Literature DB >> 24637360

Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia.

Elisabeth Walsby1, Andrea Buggins2, Stephen Devereux2, Ceri Jones1, Guy Pratt3, Paul Brennan1, Chris Fegan1, Chris Pepper1.   

Abstract

There is growing evidence that lymphocyte trafficking contributes to the clinical course of chronic lymphocytic leukemia (CLL), but to date, only static in vitro cultures have been used to study these phenomena. To address this lack of data, we have developed a dynamic in vitro model in which CLL cells experience shear forces equivalent to those in capillary beds and are made to flow through capillary-like hollow fibers lined with endothelial cells. CLL cells treated in this way increased their expression of CD62L and CXCR4 (both P < .0001) and of CD49d and CD5 (both P = .003) directly as a result of the shear force. Furthermore, CLL cells migrated through the endothelium into the "extravascular" space (mean migration, 1.37% ± 2.14%; n = 21). Migrated CLL cells had significantly higher expression of CD49d (P = .02), matrix metallopeptidase-9 (P = .004), CD38 (P = .009), CD80 (P = .04), and CD69 (P = .04) compared with CLL cells that remained in the circulation. The degree of migration observed strongly correlated with CD49d expression (r(2), 0.47; P = .01), and treatment with the CD49d-blocking antibody natalizumab resulted in significantly decreased migration (P = .01). Taken together, our data provide evidence for a novel, dynamic, and tractable in vitro model of lymphocyte migration and confirm that CD49d is a critical regulator of this process in CLL.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2014        PMID: 24637360     DOI: 10.1182/blood-2013-12-544569

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Sara J Achenbach; Susan L Slager; Timothy G Call; Wei Ding; Diane F Jelinek; Curtis A Hanson; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-04-07       Impact factor: 6.998

2.  Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jade Jones; Deanna H Wong; Mohammed Farooqui; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-06-18       Impact factor: 12.531

Review 3.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

Review 4.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

5.  TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Authors:  Emma Kennedy; Eve Coulter; Emma Halliwell; Nuria Profitos-Peleja; Elisabeth Walsby; Barnaby Clark; Elizabeth H Phillips; Thomas A Burley; Simon Mitchell; Stephen Devereux; Christopher D Fegan; Christopher I Jones; Rosalynd Johnston; Tim Chevassut; Ralph Schulz; Martina Seiffert; Angelo Agathanggelou; Ceri Oldreive; Nicholas Davies; Tatjana Stankovic; Triantafillos Liloglou; Chris Pepper; Andrea G S Pepper
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

6.  Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.

Authors:  C Pepper; A G S Buggins; C H Jones; E J Walsby; F Forconi; G Pratt; S Devereux; F K Stevenson; C Fegan
Journal:  Leukemia       Date:  2014-10-28       Impact factor: 11.528

Review 7.  Molecular Players in Hematologic Tumor Cell Trafficking.

Authors:  Javier Redondo-Muñoz; Angeles García-Pardo; Joaquin Teixidó
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

8.  Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia.

Authors:  Thomas A Burley; Andrew Hesketh; Giselda Bucca; Emma Kennedy; Eleni E Ladikou; Benjamin P Towler; Simon Mitchell; Colin P Smith; Christopher Fegan; Rosalynd Johnston; Andrea Pepper; Chris Pepper
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.575

9.  EphrinA4 plays a critical role in α4 and αL mediated survival of human CLL cells during extravasation.

Authors:  Miguel A Flores; Paula Fortea; Eva M Trinidad; Dolores García; Gloria Soler; Francisco J Ortuño; Agustín G Zapata; Luis M Alonso-Colmenar
Journal:  Oncotarget       Date:  2016-07-26

10.  RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model.

Authors:  Hana Svozilová; Zdeněk Plichta; Vladimír Proks; Radana Studená; Jiří Baloun; Michael Doubek; Šárka Pospíšilová; Daniel Horák
Journal:  Int J Mol Sci       Date:  2021-02-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.